Yunden Jinsmaa1, Patricia Sullivan1, Yehonatan Sharabi2, David S Goldstein3. 1. Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA. 2. Hypertension Unit, Chaim Sheba Medical Center and Tel-Aviv University, Tel-HaShomer, Israel. 3. Clinical Neurocardiology Section, Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: goldsteind@ninds.nih.gov.
Abstract
INTRODUCTION: Glial cytoplasmic inclusions (GCIs) containing alpha-synuclein (AS) are a neuropathologic hallmark of multiple system atrophy (MSA). Oligomerized AS is thought to be the pathogenic form of the protein. Glial cells normally express little AS, but they can take up AS from the extracellular fluid. 3,4-Dihydroxyphenylacetaldehyde (DOPAL), an obligate intermediate in the intra-neuronal metabolism of dopamine (DA), potently oligomerizes AS. In this study we tested whether DOPAL is taken up by human glial cells and augments intracellular oligomerization of AS. METHODS: DOPAL (exogenous or endogenous from co-incubation with PC12 cells) and AS (native or A53T mutant form) were added to the incubation medium of glial cells (glioblastoma or MO3.13 oligodendrocytes). Glial cellular contents of DOPAL and its intracellular metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) were measured at up to 180 min of incubation. Glial cellular AS oligomers were quantified by Western blotting. RESULTS: Neither glioblastoma nor MO3.13 cells contained endogenous catecholamines or AS. Co-incubation of the cells with DA-producing PC12 cells produced time-related increases in DOPAL and DOPAC contents. Similarly, glial cellular DOPAL and DOPAC contents increased rapidly after addition of DOPAL to the medium. After addition of native or A53T-AS, intracellular AS also increased. Incubation of glial cells with both DOPAL and AS enhanced the intracellular oligomerization of native and A53T-AS. CONCLUSIONS: DOPAL is transmissible to glial cells and enhances intracellular oligomerization of AS. An interaction of DOPAL with AS might help explain the formation of CGIs in MSA. Published by Elsevier B.V.
INTRODUCTION: Glial cytoplasmic inclusions (GCIs) containing alpha-synuclein (AS) are a neuropathologic hallmark of multiple system atrophy (MSA). Oligomerized AS is thought to be the pathogenic form of the protein. Glial cells normally express little AS, but they can take up AS from the extracellular fluid. 3,4-Dihydroxyphenylacetaldehyde (DOPAL), an obligate intermediate in the intra-neuronal metabolism of dopamine (DA), potently oligomerizes AS. In this study we tested whether DOPAL is taken up by human glial cells and augments intracellular oligomerization of AS. METHODS:DOPAL (exogenous or endogenous from co-incubation with PC12 cells) and AS (native or A53T mutant form) were added to the incubation medium of glial cells (glioblastoma or MO3.13 oligodendrocytes). Glial cellular contents of DOPAL and its intracellular metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) were measured at up to 180 min of incubation. Glial cellular AS oligomers were quantified by Western blotting. RESULTS: Neither glioblastoma nor MO3.13 cells contained endogenous catecholamines or AS. Co-incubation of the cells with DA-producing PC12 cells produced time-related increases in DOPAL and DOPAC contents. Similarly, glial cellular DOPAL and DOPAC contents increased rapidly after addition of DOPAL to the medium. After addition of native or A53T-AS, intracellular AS also increased. Incubation of glial cells with both DOPAL and AS enhanced the intracellular oligomerization of native and A53T-AS. CONCLUSIONS:DOPAL is transmissible to glial cells and enhances intracellular oligomerization of AS. An interaction of DOPAL with AS might help explain the formation of CGIs in MSA. Published by Elsevier B.V.
Authors: Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek Journal: Proc Natl Acad Sci U S A Date: 2011-02-15 Impact factor: 11.205
Authors: Petra Pasanen; Liisa Myllykangas; Maija Siitonen; Anna Raunio; Seppo Kaakkola; Jukka Lyytinen; Pentti J Tienari; Minna Pöyhönen; Anders Paetau Journal: Neurobiol Aging Date: 2014-03-26 Impact factor: 4.673
Authors: Stanley B Prusiner; Amanda L Woerman; Daniel A Mordes; Joel C Watts; Ryan Rampersaud; David B Berry; Smita Patel; Abby Oehler; Jennifer K Lowe; Stephanie N Kravitz; Daniel H Geschwind; David V Glidden; Glenda M Halliday; Lefkos T Middleton; Steve M Gentleman; Lea T Grinberg; Kurt Giles Journal: Proc Natl Acad Sci U S A Date: 2015-08-31 Impact factor: 11.205
Authors: Kim M A De Kleijn; Wieteke A Zuure; Jolien Peijnenborg; Josje M Heuvelmans; Gerard J M Martens Journal: Cells Date: 2019-09-17 Impact factor: 6.600
Authors: Meghan L Bucher; Caitlyn W Barrett; Connor J Moon; Amanda D Mortimer; Edward A Burton; J Timothy Greenamyre; Teresa G Hastings Journal: NPJ Parkinsons Dis Date: 2020-11-13
Authors: Rodrigo Cataldi; Sean Chia; Katarina Pisani; Francesco S Ruggeri; Catherine K Xu; Tomas Šneideris; Michele Perni; Sunehera Sarwat; Priyanka Joshi; Janet R Kumita; Sara Linse; Johnny Habchi; Tuomas P J Knowles; Benedetta Mannini; Christopher M Dobson; Michele Vendruscolo Journal: Commun Biol Date: 2021-01-04